

Food and Drug Administration  
Center for Biologics Evaluation and Review

SUMMARY MINUTES  
115<sup>th</sup> Meeting of the BLOOD PRODUCTS ADVISORY COMMITTEE

April 5, 2017  
Thomas Douglas Conference Center  
10000 New Hampshire Avenue, Silver Spring, MD 20903

**Committee Members**

Sridhar V. Basavaraju, M.D., FACEP  
Meera B. Chitlur, M.D.  
Michael DeVan, M.D., F.C.A.P., CDR MC  
USN  
Miguel Escobar, M.D. +  
John B. Holcomb, M.D., F.A.C.S. #  
Susan F. Leitman, M.D.  
Norma B. Lerner, M.D., M.P.H.  
Thomas Ortel, M.D., Ph.D.  
Margaret V. Ragni, M.D., M.P.H.  
Robert J. Rees, MHA, MT(ASCP)  
Sonja Sandberg, SB., Ph.D.  
Christopher Stowell, M.D., Ph.D. (Chair)  
Kathleen Sullivan, M.D., Ph.D. +

**FDA Participants**

Carolyn Wilson, Ph.D.  
CD Atreya, Ph.D.  
Hira Nakhasi, Ph.D.  
Sanjai Kumar, Ph.D.

**Temporary Voting Members**

James Maguire, M.D.

**Acting Consumer Representative**

Judith Baker, DrPH. MHSA

**Designated Federal Official**

LCDR Bryan Emery B.S.N. USPHS

**Committee Management Specialists**

Joanne Lipkind  
Rosanna Harvey

These summary minutes for the April 5, 2017 meeting of the Blood Products Advisory Committee were approved on 10/12/2017.

I certify that I participated in the April 5, 2017 meeting of the Blood Products Advisory Committee and that these minutes accurately reflect what transpired.

/Signed/

Bryan Emery, LCDR  
Designated Federal Official

/Signed/

Christopher P. Stowell., M.D., Ph.D.,  
Chair

# Did not attend

+ Attended by phone

The Chair, Dr. Christopher Stowell, called the meeting of the Blood Products Advisory Committee to order at 8:30 a.m. EST on April 5, 2017. The DFO, LCDR Bryan Emery, read into the official record the Conflicts of Interest Statement pertaining to the meeting participants.

## QUICK SUMMARY

### **Topic II: Review of the Research Programs in the Laboratory of Emerging Pathogens, Division of Emerging Transfusion-Transmitted Diseases, OBRR**

Before discussing the site visit report in the closed session, the Committee heard the following presentations:

- Overview of CBER Research Programs by Carolyn Wilson, Ph.D., CBER, FDA
- Overview of OBRR Research Programs by C.D. Atreya, Ph.D., OBRR, FDA
- Overview of the Division of Emerging Transfusion Transmitted Diseases (DETTD) Research Program by Hira Nakhasi, Ph.D., OBRR, FDA
- Overview of the Laboratory of Emerging Pathogens (LEP) by Sanjai Kumar, Ph.D., OBRR, FDA

An Open Public Hearing was announced. No presentations were made by the public during the Open Public Hearing.

The Committee then met in closed session to permit discussion where disclosure would constitute a clearly unwarranted invasion of personal privacy.

After the Closed session discussions were completed, the Chair, Dr. Christopher Stowell, adjourned the meeting at approximately 12:15 p.m.

Additional information and details may be obtained from the transcript and the recording of the webcast of the meeting that may be viewed at:

<https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/BloodProductsAdvisoryCommittee/ucm554807.htm>